Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2007

View Archived Issues

Human papillomavirus vaccine 16/18 shows promise in phase III trial

Pharmacological activity of DZ-697b investigated in vitro

KDN-7438: a novel TF/FVIIa inhibitor with anticoagulant activity in vivo

Adenosine A2A agonism decreases acute inflammation and improves posthemorrhagic vasospasm in rats

Adenosine A2A antagonism has no effect on dopamine depletion-induced deficits in cognition

Epeius' targeted gene delivery system Rexin-G enters advanced phase I/II trials

Cell Genesys completes enrollment of phase III study of GVAX immunotherapy

Catalyst begins phase II trial of CPP-109 for cocaine dependence

Recent patents disclose new agents for respiratory and allergic disorders

Recent patents describe new treatment options for endocrine-related disorders

Novel therapeutic agents for obesity and lipoprotein disorders described in recent patents

J-30: a novel microtubule-disrupting agent with antitumor efficacy in vivo

Novel HDAC inhibitor described by CrystalGenomics

Fludara tablet launched in Japan

OT-551 holds promise for oncology and inflammatory conditions

Ziopharm reports positive interm data for phase II trial of ZIO-201

Critical Therapeutics begins enrollment for phase IV trial of Zyflo CR

Update on Progen's phase III trial design for liver cancer

Health Canada approves phase I trials of WBI-1001 for psoriasis

VivaGel trial begins in sexually active young women

Tercica and Genentech to codevelop Nutropin AQ and Increlex combination drug

Valeant selects pre-IND candidates for potassium-channel opener program

Inspire plans phase III trials of epinastine nasal spray for rhinitis

Peregrine advances study of bavituximab for HCV/HIV coinfection

Initial enrollment milestone reached in Vical's phase II CMV study

BioVant shows promise as adjuvant in H5N1 avian flu vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...